Wednesday, October 3, 2012
Astex Pharmaceuticals Inc., of Dublin, Calif., said it started a Phase II study evaluating SGI-110, a small-molecule DNA-hypomethylating agent, in combination with carboplatin in platinum-resistant recurrent ovarian cancer patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.